Lilly’s EloraTZP Moves Toward Phase 3: What Amylin Plus Tirzepatide Could Add

Lilly’s latest pipeline update points to Phase 3 studies of eloralintide plus tirzepatide. The combination’s Phase 2 weight-loss findings are notable, but discontinuations and formulation changes deserve equal attention.

For research use only. Not for human consumption.